Hyphens Pharma International

Hyphens’ CFO Fang Lee Wei sayS the counter was “under-recognised and severely undervalued” in its first 18 months since listing.

On August 13, Hyphens Pharma posted a 32% y-o-y surge in earnings of $2.2 million for 2Q20 ended June, and $4.3 million for the 1H20, which represented a 39.8% growth.

The company’s main business lines enjoyed higher turnover, with growth especially strong from its proprietary brands of products.

Tan Chwee Choon, an executive director of Hyphens Pharma International, has been steadily selling shares on the open market. The most recent sale was made on July 22 when he sold 500,000 shares for $300,000, or an average price of 60 cents each. With this

Take a look at these three stocks this week: UMS Holdings, Hyphens Pharma, Mapletree Industrial Trust

PhillipCapital has initiated an “accumulate” call for Hyphens Pharma International Ltd with a target price of 43.5 cents, 3.6% higher than last closed price of 42 cents.

Hyphens Pharma shares climbed 4.7% to 33.5 cents as at 11.58am on Tuesday following news that its patent for Ceradan Advanced has been granted in the UK on Monday evening.

SINGAPORE (20 Dec) : Eight in 10 medical practitioners say Singapore’s healthcare system should focus more on disease prevention as Singaporeans live longer and are more likely to contract a chronic illness at an earlier age. Moreover, nearly half or 49

SINGAPORE (Nov 8): SAC Capital has initiated coverage on Hyphens Pharma International, a specialty pharmaceutical and consumer healthcare group, with a “buy” rating and target price of 28.5 cents.

SINGAPORE (July 10): Hyphens Pharma International has launched its so-called "next generation" Ceradan cream.